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Abstract.  Dendrobium candidum  Wall ex Lindl. 
(D. candidum) is a traditional Chinese medicine widely used 
in Asia. The present study has showed that D. candidum 
exerted an anti-metastatic effect in mice injected with 
26-M3.1 colon carcinoma cells. D. candidum showed the 
most marked tumor inhibitory rate of 64.5% at a dose of 
400 mg/kg body weight (b.w). The mRNA and protein expres-
sion of Bax in lung tissue of D. candidum-treated mice was 
shown to be higher as compared with control mice, whereas 
the mRNA and protein expression of Bcl-2 showed the 
opposite trend. Decreased mRNA and protein expression of 
MMP and increased expression of TIMPs was demonstrated 
in lung tissues by quantitative polymerase chain reaction and 
western blot assays. D. candidum reduced the serum cyto-
kine levels of IL-6, IL-12, TNF-α and IFN-γ to a greater 
extent as compared with the control mice, and administration 
of 400 mg/kg b.w. resulted in a lower serum cytokine levels 
as compared with mice treated with 200 mg/kg b.w. Eleven 
compounds were in the D. candidum leaf, of which the 
functional contents may help to generate novel treatments for 
the prevention of lung metastases. The results of the present 
study have demonstrated that D. candidum had a potent in 
vivo antitumor and anti-metastatic effect in BALB/c mice 
injected with 26-M3.1 cells.
Introduction
Dendrobium is a large genus of orchids, and Dendrobium 
candidum Wall. ex Lindl. (D. candidum) is a functional analog of 
Dendrobium moniliforme (L.) Sw. (1,2). It is a traditional Chinese 
medicinal herb that is used either raw or processed for health-
care products in China (3). D. candidum contains water-soluble 
polysaccharides, phenanthrenes and numerous amino acids. 
High contents of chrysotoxen and erianin may have inhibitory 
activities in liver cancer and ehrlich ascites carcinoma cells (4).
Metastasis is defined as the spread of cancer cells from one 
organ or area to another adjacent organ or location (5) and it 
is considered that malignant tumor cells have the capacity to 
metastasize. Cancer can occur in cells of a tissue that are geneti-
cally mutated in a progressive manner, resulting in cancer stem 
cells possessing a malignant phenotype (6). Metastasis is the 
leading cause of mortality among cancer patients, and involves 
the spread of cancer from a primary site and formation of new 
tumors in distant organs (7). Matrix metalloproteinases (MMPs) 
function in numerous physiological and pathological processes, 
including embryonic development, morphogenesis, reproduc-
tion, tissue remodeling, arthritis, cardiovascular disease and 
metastasis (8). MMP activity is inhibited by specific endogenous 
tissue inhibitors of metalloproteinases (TIMPs) (9). To prevent 
the majority of cancer types, improved treatments against metas-
tasis are needed (10).
D. candidum has been previously shown to exhibit strong 
in vitro anticancer effects on HeLa S3 human cervical carci-
noma cells and HepG2 liver cancer cells (9). In the present study, 
the anti-metastatic effects of D. candidum were investigated 
in mice injected with 26-M3.1 colon carcinoma cells, and the 
molecular mechanisms underlying the anti-metastatic effects of 
the D. candidum were studied. The in vivo anti-metastatic effects 
were determined by tumor count, cytokine levels, and mRNA 
and protein expression experiments. The association between the 
anticancer activities and functional components of D. candidum 
was additionally explored.
Materials and methods
Preparations of D. candidum. D. candidum was purchased 
from Shanghai Pharmacy Co., Ltd. (Shanghai, China). The 
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D. candidum was stored at ‑80˚C and freeze‑dried to produce 
a powder. A 20-fold volume of boiling water was added to the 
powdered sample and extracted twice by stirring overnight. 
The aqueous extract was evaporated and concentrated using a 
rotary evaporator (N-1100; Eyela, Tokyo, Japan).
Anti‑metastatic effects of D. candidum in mice bearing 
26 M3.1 cells. The following experiment was performed 
according to the methods of a previous study (11). 26-M3.1 
colon carcinoma cells were obtained from Professor Yoon 
(Department of Food and Nutrition, Yuhan University, 
Bucheon, South Korea). The metastatic cells were cultured in 
Eagle's minimum essential medium (Gibco-BRL, Carlsbad, 
CA, USA) supplemented with 7.5% FBS (fetal bovine serum), 
a vitamin solution, sodium pyruvate, non-essential amino 
acids and L-glutamine (Gibco-BRL) by 5% CO2 at 37˚C. The 
6-week-old female Balb/c mice (Experimental Animal Center 
of Chongqing Medical University, Chongqing, China) were 
induced lung metastasis by injecting colon 26-M3.1 cells. 
The experimental mice were divided three groups, there were 
20 mice in each group. The control group of mice was without 
any treatment for 2 weeks. The D. candidum group mice were 
treated with D. candidum aqueous extract solutions (200 and 
400 mg/kg b.w.) by gavage for 2 weeks. After 2 weeks, all 
the mice were intravenously inoculated with 26-M3.1 cells at 
the concentration of 2.5x104/mouse. Two days later, the mice 
were sacrificed and the lungs of 10 mice in each group were 
fixed in Bouin's solution (saturated picric acid: formalin: acetic 
acid; 15:5:1, v/v/v) (12). Then the rates of metastasis were 
determined by counting tumor colonies in the photos (Canon 
D550; Canon, Tokyo, Japan). Inhibitory rate = [(lung tumor 
number of control mice - lung tumor number of D. candidum 
treated mice)/lung tumor number of control mice] x 100%. The 
other lungs of 10 mice in each group were tested for reverse 
transcription (RT)-PCR and western blot assays. The protocol 
for these experiments was approved by the Animal Ethics 
Committee of Chongqing Medical University.
Analysis of IL‑6, IL‑12, TNF‑α and IFN‑γ cytokines in serum 
by ELISA. For the serum cytokine assay, blood from the 
inferior vena cava was collected in a tube and centrifuged at 
1100 x g and 4˚C for 10 min. The serum was aspirated and 
assayed as described below. Concentrations of cytokines of 
IL-6, IL-12, TNF-α and IFN-γ in serum were measured using 
mouse IL-6, IL-12, TNF-α and IFN-γ ELISA kits according 
to the manufacturer's instructions (Biolegend, San Diego, CA, 
USA). Briefly, biotinylated antibody reagent was added to 
96-well plates, then supernatants of homogenized serum were 
added and the plates were incubated at 37˚C in CO2 for 2 h. 
After washing with phosphate-buffered saline (PBS), strepta-
vidin-horseradish peroxidase (HRP) solution was added and 
the plate was incubated for 30 min at room temperature. The 
absorbance was measured at 450 nm using a microplate reader 
(iMark; Bio-Rad, Hercules, CA, USA) (13).
RT‑PCR. RT-PCR was performed according to the methods 
descirbed in a previous study (11). The RNA of lung tissue was 
treated with TRIzol reagent (Invitrogen Life Technologies, 
Carlsbad, CA, USA) for extraction. After total RNA was 
digested with RNase-free DNase (Roche, Diagnostics Basel, 
Switzerland) for 15 min at 37˚C, then the  digested RNA was 
purified by RNeasy kit (Qiagen, Hilden, Germany). The cDNA 
was synthesized from 2 µg of total RNA at 37˚C for l h with 
AMV reverse transcriptase (GE Healthcare, Little Chalfont, 
Buckinghamshire, UK) (2). Sequences of Bax, Bcl-2, MMPs 
and TIMPs were specifically amplified (Table I) by  thermal 
cycler (Eppendorf, Hamburg, Germany). The PCR products 
were separated in 1.0% agarose gels and visualized with 
ethidium bromide staining.
Protein extraction and western blot analysis in the gastric 
tissue. Total lung tissue protein was obtained with radioim-
munoprecipitation assay buffer as described (12). Protein 
concentrations were determined with a Bio-Rad protein assay 
kit (Bio-Rad, Hercules, CA, USA). For the western blot anal-
ysis, aliquots of the lysate containing 30-50 µg protein were 
separated by SDS-PAGE and then electrotransferred onto 
a nitrocellulose membrane (Schleicher and Schuell, Keene, 
NH, USA). The membranes were subjected to immunoblot 
analysis and the proteins were visualized by an enhanced 
chemiluminescence (ECL) method (Amersham ECL GST 
Western Blotting Detection kit, product code: RPN1237; 
GE Healthcare) then transferred onto a polyvinylidene fluoride 
membrane (GE Healthcare), prior to blocking with 5% non-fat 
milk and hybridization with primary antibodies (diluted 
1:1,000). The antibodies against Bax, Bcl-2, MMPs and 
TIMPs were obtained from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA, USA). The membranes were then incubated 
with a horseradish peroxidase-conjugated secondary antibody 
(Santa Cruz Biotechnology, Inc.) for 1 h at room temperature. 
The blots were washed three times with PBS-Tween and then 
developed by ECL using GE Healthcare ECL prime western 
blotting detection reagent (GE Healthcare).
Component analysis by nuclear magnetic resonance (NMR). 
Dried D. candidum was refluxed and extracted three times with 
10 times amount of ethyl acetate. The ethyl acetate extract was 
obtained after 1 h for every reflux extraction and decompression 
concentrating extraction. The total ethyl acetate extract was 
extracted by anhydrous ethanol three times. The ethanol extract 
thus produced was resuspended in water before extraction by 
petroleum ether, chloroform and butanol, respectively, as follows. 
Firstly, the ethyl acetate extract was treated by gradient elution in 
a silica gel column with a petroleum ether-ethyl acetate system. 
Secondly, the chloroform extract was treated by gradient elution 
in a silica gel column with a petroleum chloroform-methanol 
system. Finally, the butanol extract was agitated by water ultra-
sonic, filtered and then eluted by an HP2MGL macroporous 
resin column with water, 10% ethanol, 30% ethanol and 60% 
ethanol, respectively. Following elution, the different solvents 
had eluted various compounds, and their composition could be 
identified by NMR (Varian INOVO 400; Varian Inc., Palo Alto, 
CA, USA). The NMR was set at an 1H frequency of 300 MHz, 
temperature of 25˚C, pulse length of 8 µsec and spin speed 
of 20 Hz, and scanned 64 times. The 1H-NMR spectra were 
recorded using a standard high-resolution magicangle spinning 
probe with magic-angle gradient.
Statistical analysis. Data are presented as the means ± standard 
deviation. Differences between the mean values for individual 
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groups were assessed by one-way analysis of variance with 
Duncan's multiple range test. P<0.05 was considered to indi-
cate a statistically significant difference. SAS, version 9.1 
(SAS Institute, Inc., Cary, NC, USA) was used for statistical 
analyses.
Results
In vivo anti‑metastatic effects of D. candidum. 26-M3.1 colon 
carcinoma cells were used to evaluate the anti-metastatic effects 
of D. candidum in vivo. Prophylactic inhibition of tumor metas-
tasis by D. candidum was evaluated by using an experimental 
mouse metastasis model (Fig. 1). D. candidum‑treated mice had 
significantly fewer lung metastatic colonies as compared with 
control mice (number of metastatic tumors, 62±6; P<0.05). A 
dose of 400 mg/kg b.w. D. candidum was the most effective at 
inhibiting lung metastasis. This concentration (inhibitory rate, 
64.5%; number of metastatic tumors, 22±3) inhibited tumor 
formation and lung metastasis to a greater degree as compared 
with a dose of 200 mg/kg solution (inhibitory rate, 46.8%; 
number of metastatic tumors, 33±4).
IL‑6, IL‑12, TNF‑α and IFN‑γ serum levels in mice. The 
control mice showed the highest serum levels of IL-6, IL-12, 
TNF-α and IFN-γ. These levels were significantly decreased 
in D. candidum-treated mice (P<0.05, Table II). A higher 
concentration of 400 mg/kg b.w. D. candidum was more effec-
tive as compared with the 200 mg/kg b.w. dose in promoting a 
decrease in cytokine serum levels.
Apoptosis‑related gene expression of Bax and Bcl‑2 in the 
lung. To determine which apoptotic pathways were induced by 
D. candidum, the mice were treated with 200 and 400 mg/kg 
b.w. dose, and the lung tissues were dissected and analyzed 
for apoptosis-related gene expression by RT-PCR and western 
blotting. As shown in Fig. 2, in the presence of D. candidum, 
there were significant differences (P<0.05) in the expression of 
Bax and Bcl-2, with an increase in Bax expression and a reduc-
tion in Bcl-2 expression, as determined by RT-PCR. The Bax 
gene expression increased with D. candidium treatment, in a 
dose dependent manner, and Bcl-2 gene expression showed 
a crosscurrent when mice were treated with D. candidium 
(P<0.05). The results suggested that D. candidum induced 
apoptosis in 26-M3.1 cell-injected lung metastatic mice 
through a Bax- and Bcl-2-dependent pathway. The increased 
expression of Bax and decreased expression of Bcl-2 induced 
by 400 mg/kg D. candidum was more notable at the mRNA 
expression level, as compared with the 200 mg/kg dose. From 
these results, D. candidum showed good anticancer effects in 
its ability to induce apoptosis, and these effects were observed 
in a dose-dependent manner.
Metastasis‑related gene expression of MMPs and TIMPs in 
the lung. RT-PCR and western blot analysis was conducted 
to investigate whether the inhibitory effects of D. candidum 
on metastasis were due to gene regulation of metastatic 
mediators, such as MMPs (MMP-2 and MMP-9) and TIMPs 
(TIMP-1 and TIMP-2). The expression of MMPs and TIMPs 
was therefore analyzed in lung tissues taken from control and 
D. candidum-treated mice. As shown in Fig. 3, D. candidum 
significantly decreased the mRNA and protein expression of 
MMP-2 and MMP-9 (P<0.05), and significantly increased 
the expression of TIMP-1 and TIMP-2 (P<0.05). The most 
prominent anti-metastatic effects were associated with the 
most marked decrease in expression of MMP-2 and MMP-9, 
together with the most marked increase in expression of 
TIMP-1 and TIMP-2. These results suggested that the higher 
400 mg/kg dose of D. candidum, cultivated in the presence 
of sulfur, could elicit a stronger anti-metastatic activity as 
compared with the lower 200 mg/kg dose.
Content of the D. candidum leaf. Eleven compounds were 
isolated and identified from the D. candidum leaf. Compound 1 
was obtained as a clear crystal, and the 1H-NMR spectrum of 
this compound was as follows: δ 6.92 (2H, d), 6.62 (2H, d), 6.06 
(2H, s), 6.03 (1H, s), 2.65 (4H, m). This compound was confirmed 
as dihydrogen resveratrol. Compound 2 was obtained as a white 
powder, and the 1H-NMR spectrum of this compound was as 
follows: δ 6.98 (2H, d), 6.74 (2H, d), 6.62 (1H, s), 6.47 (1H, d), 
4.83 (1H,d), 4.63 (1H, d), 3.1-3.8 (12H), 3.73 (3H, s), 3.69 (3H, s), 
2.74 (4H, m). This compound was confirmed as dendromonili-
side E. Compound 3 was obtained as a black red needle, and the 
1H-NMR spectrum of this compound was as follows: δ 11.00 
(1H, s), 8.15 (1H, d), 6.06 (2H, s), 8.07 (1H, d), 6.95 (1H, s), 6.83 
(1H, s), 6.15 (1H, s), 3.96 (3H, s), 3.93 (3H, s). This compound was 
confirmed as denbinobin. Compound 4 was obtained as a color-
less needle, and the 1H-NMR spectrum of this compound was 
as follows: δ 4.72 (2H, m), 3.85 (1H, d), 6.06 (2H, s), 2.53 (1H, 
d), 2.49 (1H, t), 2.39 (1H, dd), 2.21 (1H, dd), 1.64 (1H, m), 1.35 
(3H, s), 1.03 (3H, d), 0.95 (3H, d). This compound was confirmed 




  Forward 5'-AAGCTGAGCGAGTGTCTCCGGCG-3'
  Reverse 5'-CAGATGCCGGTTCAGGTACTCAGTC-3'
Bcl-2 
  Forward 5'-CTCGTCGCTACCGTCGTGACTTGG-3'
  Reverse 5'-CAGATGCCGGTTCAGGTACTCAGTC-3'
MMP-2
  Forward 5'-CTTCTTCAAGGACCGGTTCA-3'
  Reverse 5'-GCTGGCTGAGTACCAGTA-3'
MMP-9
  Forward 5'-TGGGCTACGTGACCTATGAC-3'
  Reverse 5'-GCCCAGCCCACCTCCACTCC-3'
TIMP-1
  Forward 5'-GTCAGTGAGAAGCAAGTCGA-3'
  Reverse 5'-ATGTTCTTCTCTGTGACCCA-3'
TIMP-2
  Forward 5'-TGGGGACACCAGAAGTCAAC-3'
  Reverse 5'-TTTTCAGAGCCTTGGAGGAG-3'
GAPDH
  Forward 5'-CGGAGTCAACGGATTTGGTC-3'
  Reverse 5'-AGCCTTCTCCATGGTCGTGA-3'
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as aduncin. Compound 5 was obtained as a white needle, and 
the 1H-NMR spectrum of this compound was as follows: δ 8.25 
(1H, s), 8.10 (1H, s), 5.90 (1H, d), 4.66 (1H, dd), 3.5-4.2 (4H, 
m). This compound was confirmed as adenosine. Compound 6 
was obtained as a white powder, and the 1H-NMR spectrum 
of this compound was as follows: δ 7.95 (1H, d), 5.85 (1H, d), 
Table II. Serum IL-6, IL-12, TNF-α, and IFN-γ levels of mice bearing 26-M3.1 cells treated with D. candidum.
Treatment IL-6 IL-12 TNF-α IFN-γ
Control (untreated) 235.7±33.8a 712.1±55.8a 84.1±12.0a 80.5±7.7a
D. candidum (mg/kg)
  200 172.7±21.6b 571.7±42.9b 61.2±4.9b 63.8±5.9b
  400 113.0±26.1c 338.6±39.7c 50.6±6.6c 44.8±6.2c
a-cMean values with different letters in the same column are significantly different (P<0.05) according to Duncan's multiple range test. D. can‑
didum, Dendrobium candidum.
Figure 1. Inhibitory effects of different concentrations of Dendrobium candidum aqueous extract on the metastasis of tumors produced by colon 26-M3.1 cells 
in Balb/c mice.
Figure 2. Effects of aqueous extract from D. candidum on the mRNA (left) and protein (right) expression of Bax and Bcl-2 in mice. Fold ratio = gene 
expression/GAPDH x control numerical value (control fold ratio: 1). a-c,A-CMean values with different letters over the bars are significantly different (P<0.05) 
according to Duncan's multiple-range test. a,AP<0.05, vs. the control; b,BP<0.05, vs. the 200 mg/kg D. candidum dose; c,CP<0.05, vs. the 400 mg/kg D. candidum 
dose. D. candidum, Dendrobium candidum; RT-PCR, quantitative polymerase chain reaction. 
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5.66 (1H, d), 3.2-4.3 (5H, m). This compound was confirmed as 
uridine. Compound 7 was obtained as a clear crystal, and the 
1H-NMR spectrum of this compound was as follows: δ 10.60 
(1H, s), 7.92 (1H, s), 6.45 (2H, s), 5.66 (1H, d), 3.4-4.4 (5H, m). 
This compound was confirmed as guanosine. Compound 8 was 
obtained as a white powder, and the 1H-NMR spectrum of this 
compound was as follows: δ 7.65 (1H, d), 7.41 (2H, d), 6.85 (2H, 
d), 6.33 (1H, d), 4.17 (2H, t), 1.69 (2H,m), 1.25 (54H, m), 0.85 
(3H, t). This compound was confirmed as defuscin. Compound 9 
was obtained as a white powder, and the 1H-NMR spectrum 
of this compound was as follows: δ 7.45 (2H, d), 6.82 (2H, d), 
6.81 (1H, d), 5.83 (1H, d), 4.16 (2H, t), 1.67 (2H, m), 1.23 (54H, 
m), 0.88 (3H, t). This compound was confirmed as n-triacontyl 
cis-p-coumarate. Compound 10 was obtained as a white powder, 
and the 1H-NMR spectrum of this compound was as follows: 
δ 2.35 (2H, t), 1.62 (2H, m), 1.25 (24H, m), 0.88 (3H, t). This 
compound was confirmed as hexadecanoic acid. Compound 11 
was obtained as a white powder, and the 1H-NMR spectrum 
of this compound was as follows: δ 3.85 (2H, t), 1.75 (2H, m), 
1.45 (2H, m), 1.22 (54H, m), 0.85 (3H, t). This compound was 
confirmed as hentriacontane.
Discussion
Although D. candidum has been used as a traditional Chinese 
medicine, there has been little scientific research regarding its 
mechanism of action. D. candidum contains high concentra-
tions of benzenes and their derivatives, phenolic, lignans, 
lactone, flavonoids and 18 novel D. candidum pigments (14). 
D. candidum has been previously reported to have various 
therapeutic effects on numerous pathological conditions, 
including inflammation, immunity, hyperglycemia and 
cancer (15). 
Lower levels of IL-6, IL-12, IFN-γ and TNF-α cytokines 
are indicative of improved anticancer effects (16,17). IL-6 is 
regarded as an important tumor-promoting factor in various 
types of human cancer. An increased expression of IL-6 
has been found in patients with cancer, in serum and tumor 
tissue (18). IL-12 has been shown to contribute to tumor 
eradication, through IFN-γ-dependent induction of the 
anti-angiogenic factors interferon-inducible protein 10 and 
monokine induced by gamma interferon (19). In addition, a 
previous study has shown that drugs targeting TNF-α may be 
Figure 3. Effects of aqueous extract from D. candidum on the mRNA (left) and protein (right) expression of MMPs and TIMPs in mice. Fold ratio = gene 
expression/GAPDH x control numerical value (control fold ratio: 1). a-c,A-CMean values with different letters over the bars are significantly different (P<0.05) 
according to Duncan's multiple-range test. a,AP<0.05, vs. the control; b,BP<0.05, vs. the 200 mg/kg D. candidum dose; c,CP<0.05, vs. the 400 mg/kg D. candidum 
dose. D. candidum, Dendrobium candidum; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of matrix metalloproteinases; RT-PCR, quantitative 
polymerase chain reaction.
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useful for the treatment of cancers (13). In the present study, 
it was observed that the levels of IL-6, IL-12, TNF-α and 
IFN-γ in mice injected with 26-M3.1 cells were markedly 
decreased following D. candidum treatment. Based on this 
study, D. candidum showed a strong preventive effect on the 
development of lung metastases.
Tumor cells are able to migrate to another site, penetrate the 
vessel walls, continue to multiply and eventually form another 
tumor. Colon 26-M3.1 carcinoma cells have been previously 
used to evaluate anti-metastatic effects in vivo (20). Based on 
in vivo data from previous studies, 26-M3.1 colon carcinoma 
cells were used to examine the effects of D. candidum on 
metastasis in mice. The results further proved the activity of 
D. candidum, and the observed anticancer effects occurred in 
a dose-dependent manner.
Apoptosis is a fundamental cell event, and understanding 
its mechanisms of action will have a significant effect on anti-
tumor therapy. The Bcl-2 family, which includes promoters 
(Bax and Bid) and inhibitors (Bcl-2 and Bcl-xL), is a key regu-
lator in mitochondria-mediated apoptosis (21). In the present 
study, the gene and protein expression of Bax was increased, 
whereas the protein expression of Bcl-2 was decreased 
following treatment with D. candidum. Based on the gene 
expression results, D. candidum showed strong activity in 
promoting apoptosis in cancer.
MMPs comprise a family of zinc-dependent endopep-
tidases that function in tumorigenesis and metastasis (22). 
MMPs can cleave the majority of all extracellular matrix 
(ECM) substrates. Degradation of the ECM is a key event in 
tumor progression, invasion and metastasis (23). Among the 
MMP family members, MMP-2 and MMP-9 are molecules 
important for cancer invasion, and have been shown to be 
highly expressed in cancer cells (24). Inhibition of MMP 
activity is useful for controlling tumorigenesis and metas-
tasis (25). TIMPs are naturally occurring inhibitors of MMPs 
that prevent catalytic activity by binding to activated MMPs, 
thereby blocking the degradation of the ECM. Disturbances in 
the ratio between MMPs and TIMPs have been observed during 
tumorigenesis (26). Maintaining the balance between MMPs 
and TIMPs, or increasing TIMP activity, are useful methods 
by which to control tumor metastasis (27). In the present study, 
strong anti-metastatic effects were correlated with a reduction 
of MMPs and an increase of TIMPs following administra-
tion of D. candidum in mice. From the results, D. candidum 
showed a strong anti-metastatic effect and, therefore, may be a 
functional drug for cancer prevention.
Numerous compounds were isolated and identified by 
NMR of the D. candidum leaf in the present study. Resveratrol 
is an antioxidant that has been often recommended for use as 
treatment in patients with colon cancer (28). Denbinobin is a 
biologically active chemical that has been demonstrated to inhibit 
colon cancer growth both in vitro and in vivo (29). Aduncin is 
a unique component that has only been found in Dendrobium. 
Aduncin may have anticancer effects, but its function requires 
further research (30). Adenosine serves as a physiological 
regulator and acts as a cardio-, neuro- and chemo-protector, and 
as an immunomodulator. Adenosine has been shown to exert 
anticancer effects at certain concentration. When administered 
in combination with chemotherapy, adenosine can enhance 
the chemotherapeutic index and acts as a chemoprotective 
agent (31). The availability of uridine can alter the sensitivity 
of tumor cells to antimetabolites. Adenine is incorporated into 
polynucleotides and the two compounds have been identified as 
important cancer-associated substances (32). Defuscin, n-tria-
contyl cis-p-coumarate, hexadecanoic acid and hentriacontane 
have also shown functional activities in human health (33,34). 
Taken together, these compounds all exhibit anticancer activi-
ties, and with the high content of functional compounds, this 
may explain why D. candidum showed a functional effect in 
cancer prevention. The synergy of these bioactive components 
may increase the anticancer effects of D. candidum.
In summary, the present study found that D. candidum has 
potent in vivo anti-metastatic activity, particularly in the inhibi-
tion of in vivo tumor metastasis. The analysis of cytokine levels, 
as well as mRNA and protein expression, has provided a mecha-
nistic basis for these functional effects and a scientific basis for 
the development of D. candidum in cancer therapy.
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